LivaNova PLC Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 01, 2023 at 06:00 am EDT
Share
LivaNova PLC reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 286.1 million compared to USD 252.6 million a year ago. Net loss was USD 7.3 million compared to USD 107.3 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 2.01 a year ago. Diluted loss per share from continuing operations was USD 0.14 compared to USD 2.01 a year ago.
For the nine months, sales was USD 843.4 million compared to USD 746.9 million a year ago. Net income was USD 1.2 million compared to net loss of USD 87.9 million a year ago. Basic earnings per share from continuing operations was USD 0.02 compared to basic loss per share from continuing operations of USD 1.64 a year ago. Diluted earnings per share from continuing operations was USD 0.02 compared to diluted loss per share from continuing operations of USD 1.64 a year ago.
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Companyâs next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.